Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

OncoCyte Corporation (OCX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.7333+0.0035 (+0.48%)
At close: 04:00PM EDT
0.7200 -0.01 (-1.81%)
After hours: 05:55PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.7298
Open0.7300
Bid0.7200 x 800
Ask0.8190 x 1200
Day's Range0.7218 - 0.7866
52 Week Range0.6800 - 3.7300
Volume119,722
Avg. Volume304,518
Market Cap86.976M
Beta (5Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-0.7710
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OCX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • OncoCyte Corporation
    Daily – Vickers Top Insider Picks for 09/27/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GlobeNewswire

    Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS

    Palmetto GBA Conveys Validity of Broader Claim for DetermaRx As a Risk of Recurrence Test Expanding Market UtilityIRVINE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey today, announced that the Advisory Panel for clinical diagnostic laboratory tests (CDLT) has unanimously recommended tha

  • GlobeNewswire

    Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference

    IRVINE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that its management team will participate at the Lake Street 6th Annual Best Ideas Growth Conference on Wednesday, September 14, 2022 at the Yale Club in New York City, NY. About OncocyteOncocyte is a precision diagnos

  • GlobeNewswire

    Oncocyte Announces Five-Year VA Contract for DetermaRx

    IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that the US Department of Veterans Affairs (“VA”), the largest integrated health care system in the United States, has awarded a Federal Supply Schedule Contract for the Company’s DetermaRx™ test. The VA provides care

Advertisement
Advertisement